Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-08-09
2011-08-09
Blanchard, David J. (Department: 1619)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S141100, C424S154100, C435S069600, C435S070210, C530S387100, C530S387300, C530S388100, C530S388750
Reexamination Certificate
active
07993641
ABSTRACT:
An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereofcharacterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence.The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.
REFERENCES:
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5968509 (1999-10-01), Gorman et al.
patent: 6706265 (2004-03-01), Bolt et al.
patent: WO 93/19196 (1993-09-01), None
Fundamental Immunology, 3rd Edition, William E. Paul., ed., pp. 292-295, 1993.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Colman, Research in Immunology 145:33-36, 1994.
Rudikoff et al; PNAS 79:1979, 1982.
Bolt. S. et al., “The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties,” Eur. J. Immunol., 23(2):403-411 (1993).
Clark M. et al., “Advantages of rat monoclonal antibodies,” Immunol. Today, 4:100-101 (1983).
Clark M.R. & H. Waldmann, “T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies,” J. Natl. Cancer Inst. 79:393-1401 (1987).
Cockett M.I. et al., “High level expression of tissue inhibitor of metalloproteinases in chinese hamster ovary cells using glutamine synthetase gene amplification,” Bio/technology, 8:662-667 (1990).
Friend P.J. et al., “Phase I study of an engineered aglycosylated humanised CD3 antibody in renal transplant rejection,” Transplantation, 68(11):1632-37 (1999).
Isaacs J.D. et al, “Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential,” J. Immunol., 148:3062-71 (1992).
Page M.J. & M.A. Sydenham, “High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells,” Biotechnology, 9:64-68 (1991).
Routledge E.G. et al., “A humanized monovalent CD3 antibody which can activate homologous complement,” Eur. J. Immunol., 21(11):2717-25 (1991).
Routledge E.G., et al., “Reshaping antibodies for therapy,” in Protein engineering of antibody molecules for prophylactic and therapeutic applications in man (ed. M. Clark) (Academic Titles, Nottingham UK), pp. 13-44 (1993).
Routledge E.G. et al., “The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody,” Transplantation, 60:847-53 (1995).
Cox, C., “Characterisation of the binding of CD3 antibodies to human lymphocytes by Flow Cyrometry”, BioAnaLab Limited, pp. 1-44 (2010).
Frewin Mark
Waldmann Herman
Blanchard David J.
BTG International Limited
Finnegan Henderson Farabow Garrett & Dunner LLP
LandOfFree
Methods of treatment using anti-CD3 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using anti-CD3 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using anti-CD3 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2784295